LUNGevity, the leading lung cancer research foundation in the U.S., has appointed Dr. Sandip Patel to its Scientific Advisory Board. His expertise will help shape key research initiatives aimed at improving lung cancer diagnosis, treatment, and patient outcomes.
“We are honored to welcome Dr. Patel to our Scientific Advisory Board,” said Dr. Charles Rudin, chair of LUNGevity’s board and deputy director at Memorial Sloan Kettering Cancer Center. “His knowledge will be invaluable as we expand our research investments and work toward meaningful advancements in lung cancer care.”
Dr. Patel, a professor at the University of California, San Diego (UCSD), specializes in early-phase clinical trials of immunotherapy and thoracic oncology. He expressed his commitment to LUNGevity’s mission, stating, “Having seen firsthand the impact of lung cancer, I am eager to contribute to research that will improve screening, treatment resistance, and patient care on a global scale.”
A graduate of Baylor College of Medicine, Dr. Patel trained at MD Anderson Cancer Center, UCLA Medical Center, and Duke University. He is triple-board-certified in internal medicine, medical oncology, and hematology and was recently named a “Top Doc” in San Diego Magazine’s “Physicians of Exceptional Excellence” survey.
At UCSD Moores Cancer Center, Dr. Patel leads the Experimental Therapeutics (Phase 1) Program and co-leads the Solid Tumor Therapeutics Program. He also serves as deputy director of the Sanford Stem Cell Clinical Institute and co-leader of the NRG Developmental Therapeutics Committee.
LUNGevity looks forward to Dr. Patel’s contributions in driving transformative research that enhances the lives of lung cancer patients.
